Since the introduction of the first biosimilar guidelines in 2005, the biosimilars field has continued to evolve. Almost 30 biosimilar molecules are currently marketed in the United States and Europe alone. While Europe has long led the way in terms of biosimilars guidelines and clinical development, other countries/regions are catching up, fast. Clinical development of biosimilars is taking place across the globe, increasingly in emerging markets. The below infographic explores the biosimilars hotspots across the globe.